Literature DB >> 8763311

A comparative study of the efficacy of 2.5% phenylephrine and 10% phenylephrine in pre-operative mydriasis for routine cataract surgery.

V Tanner1, A G Casswell.   

Abstract

It is common practice in many ophthalmic units to administer multiple applications of 10% phenylephrine in combination with an anti-cholinergic agent to ensure adequate pupil mydriasis prior to routine cataract surgery. Phenylephrine is a pure alpha-1 adrenoreceptor agonist known to produce marked systemic vasoconstriction and associated hypertension with occasional profound reflex bradycardia. Many reviews have suggested caution in the use of 10% phenylephrine in the elderly or hypertensive patient. In a prospective, randomised trial we have assessed pupil dilation comparing the efficacy of 10% phenylephrine (53 patients) versus 2.5% phenylephrine (62 patients). When administered in conjunction with 1% cyclopentolate four times over 1 hour pre-operatively, 2.5% phenylephrine was found to be as effective as 10% phenylephrine in the initiation and maintenance of mydriasis during both extracapsular and phacoemulsification cataract extraction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763311     DOI: 10.1038/eye.1996.15

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  3 in total

Review 1.  Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions.

Authors:  Seanna R Grob; Luis A Gonzalez-Gonzalez; Mary K Daly
Journal:  Clin Ophthalmol       Date:  2014-07-03

2.  Safety of tropicamide and phenylephrine in pupillary mydriasis for cataract surgery.

Authors:  Sikander A K Lodhi; Manjula V Ramsali; Dilip K Kulkarni; P Surender; Srinivasa Murty
Journal:  Saudi J Ophthalmol       Date:  2022-02-18

3.  Subconjunctival 0.1% epinephrine versus placebo in maintenance of mydriasis during vitrectomy: a randomized controlled trial.

Authors:  Rafael B de Araújo; Breno M S Azevedo; Thais S Andrade; Maria F Abalem; Mário L R Monteiro; Pedro C Carricondo
Journal:  Int J Retina Vitreous       Date:  2018-10-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.